Comparison of Deferasirox and Desferrioxamine in Term of Mean Serum Ferritin Levels in Patients of β-Thalassemia Major with Iron Overload: Effect of Deferasirox and Desferrioxamine in β-Thalassemia Major

Khadeeja Iram; Zulfiqar Ali; Fauzia Aamer; Aslam Shiekh; Maria Hassan

doi:10.54393/pjhs.v5i08.1519

Authors

Khadeeja Iram Department of Pediatric Hematology Oncology, The Children’s Hospital and Institute of Child Health, Multan, Pakistan
Zulfiqar Ali Department of Pediatric Hematology Oncology, The Children’s Hospital and Institute of Child Health, Multan, Pakistan
Fauzia Aamer Department of Pediatric Hematology Oncology, The Children’s Hospital and Institute of Child Health, Multan, Pakistan
Aslam Shiekh Department of Pediatric Hematology Oncology, The Children’s Hospital and Institute of Child Health, Multan, Pakistan
Maria Hassan Department of Pediatric Hematology Oncology, The Children’s Hospital and Institute of Child Health, Multan, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v5i08.1519

Keywords:

Deferasirox, Serum Ferritin Levels, β-Thalassemia Major, Iron Overload

Abstract

Iron chelation treatments as adjuvant therapy can reduce iron stores to minimize the related morbidity and mortality in patients with thalassemia major. Objective: To compare Deferasirox (DFX) and Desferrioxamine (DFO) in terms of mean serum ferritin levels in patients of β-thalassemia major having Iron overload. Methods: This randomized controlled trial was conducted at the Thalassemia Center of Hematology Department, “The Children's Hospital and The Institute of Child Health”, Multan, Pakistan from January 2023 to September 2023. After randomization, children in DFO group were given DFO in a dose of 50mg/kg, through subcutaneous route by infusion pump five days a week. Children in DFX group were given DFX in a dose of 30mg/kg, orally in tablet form once daily. Baseline serum ferritin levels were measured and the change in mean serum ferritin level for each group was calculated and compared for both groups after 6-months of treatment. Results: In a total of 142 children, 87 (61.3%) children were male. The mean age was 7.08 ± 2.41 years. The mean number of blood transfusions at the time of enrollment were 13.4 ± 4.2. After 6 months of treatment in DFO versus DFX groups, the net change in mean serum ferritin levels from baseline to post-treatment was 947.2 ± 454.0 µg/L for DFO and 1053.5 ± 389.8 µg/L for DFX, with no statistically significant difference between the groups (p=0.1367). Conclusions: Once-daily oral deferasirox has good compliance, acceptable tolerability and appears to have similar efficacy to desferrioxamine in reducing iron burden of transfused patients with beta thalassemia major.

References

Angastiniotis M and Lobitz S. Thalassemias: an overview. International Journal of Neonatal Screening. 2019 Mar; 5(1): 16. doi: 10.3390/ijns5010016. DOI: https://doi.org/10.3390/ijns5010016

Azman NF, Abdullah WZ, Hanafi S, Diana R, Bahar R, Johan MF et al. Genetic polymorphisms of HbE/beta thalassemia related to clinical presentation: implications for clinical diversity. Annals of Hematology. 2020 Apr; 99: 729-35. doi: 10.1007/s00277-020-03927-5. DOI: https://doi.org/10.1007/s00277-020-03927-5

De Sanctis V, Kattamis C, Canatan D, Soliman AT, Elsedfy H, Karimi M et al. β-thalassemia distribution in the old world: an ancient disease seen from a historical standpoint. Mediterranean Journal of Hematology and Infectious Diseases. 2017 Feb; 9(1): e2017018. doi: 10.4084/MJHID.2017.018. DOI: https://doi.org/10.4084/mjhid.2017.018

Ali S, Mumtaz S, Shakir HA, Khan M, Tahir HM, Mumtaz S et al. Current status of beta‐thalassemia and its treatment strategies. Molecular Genetics & Genomic Medicine. 2021 Dec; 9(12): e1788. doi: 10.1002/mgg3.1788. DOI: https://doi.org/10.1002/mgg3.1788

Yousuf R, Akter S, Wasek SM, Sinha S, Ahmad R, Haque M. Thalassemia: A Review of the Challenges to the Families and Caregivers. Cureus. 2022 Dec; 14(12): e32491. doi: 10.7759/cureus.32491. DOI: https://doi.org/10.7759/cureus.32491

Ghosh K and Ghosh K. Iron chelators or therapeutic modulators of iron overload: Are we anywhere near ideal one?. Indian Journal of Medical Research. 2018 Oct; 148(4): 369-72. doi: 10.4103/ijmr.IJMR_2001_17. DOI: https://doi.org/10.4103/ijmr.IJMR_2001_17

Entezari S, Haghi SM, Norouzkhani N, Sahebnazar B, Vosoughian F, Akbarzadeh D et al. Iron chelators in treatment of iron overload. Journal of Toxicology. 2022 May; 2022(1): 4911205. doi: 10.1155/2022/4911205. DOI: https://doi.org/10.1155/2022/4911205

Qadah T. Deferasirox versus deferoxamine in managing iron overload in patients with Sickle Cell Anaemia: a systematic review and meta-analysis. Journal of International Medical Research. 2022 Dec; 50(12): 03000605221143290. doi: 10.1177/03000605221143290. DOI: https://doi.org/10.1177/03000605221143290

Syed Z, Asif MH, Waheed R, Haider A, Ayub MA, Sidrah. Comparing deferasirox and desferrioxamine as iron chelators in patients with beta-thalassemia major. Journal of Population Therapeutics and Clinical Pharmacology. 2023 Sep; 30(17): 1937-42. doi: 10.53555/jptcp.v30i17.2880.

Xia S, Zhang W, Huang L, Jiang H. Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials. PLOS One. 2013 Dec; 8(12): e82662. doi: 10.1371/journal.pone.0082662. DOI: https://doi.org/10.1371/journal.pone.0082662

Al-Kuraishy HM and Al-Gareeb AI. Comparison of deferasirox and deferoxamine effects on iron overload and immunological changes in patients with blood transfusion-dependent β-thalassemia. Asian Journal of Transfusion Science. 2017 Jan; 11(1): 13-7. doi: 10.4103/0973-6247.200768. DOI: https://doi.org/10.4103/0973-6247.200768

Choudhary F, Rani P, Kotru M, Gomber S, Dewan P, Gupta R et al. Correlation of T-regulatory Cells and Iron Status in β-Thalassemia Major Patients. Cureus. 2023 Feb; 15(2): e35084. doi: 10.7759/cureus.35084. DOI: https://doi.org/10.7759/cureus.35084

Salem A, Desai P, Elgebaly A. Efficacy and Safety of Combined Deferiprone and Deferasirox in Iron-Overloaded Patients: A Systematic Review. Cureus. 2023 Nov; 15(11): e48276. doi: 10.7759/cureus.48276.

Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007 Apr; 115(14): 1876-84. doi: 10.1161/CIRCULATIONAHA.106.648790. DOI: https://doi.org/10.1161/CIRCULATIONAHA.106.648790

Telfer PT, Warburton F, Christou S, Hadjigavriel M, Sitarou M, Kolnagou A et al. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. Haematologica. 2009 Dec; 94(12): 1777. doi: 10.3324/haematol.2009.009118. DOI: https://doi.org/10.3324/haematol.2009.009118

Taher A, El‐Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D et al. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron‐overloaded patients with β‐thalassaemia: the ESCALATOR study. European Journal of Haematology. 2009 Jun; 82(6): 458-65. doi: 10.1111/j.1600-0609.2009.01228.x. DOI: https://doi.org/10.1111/j.1600-0609.2009.01228.x

Rasalkar DD, Lee RK, Lee V, Leung A, Cheng FW, Lam WW et al. Iron Chelation Effects of Different Treatment Protocols in Thalassaemia Major: Comparison by Magnetic Resonance T2* over sTwo Years. Hong Kong Journal of Radiology. 2012 Jun; 15(2): 88.

Arya A, Jokar S, Etemadfar P, Malekzadeh JM, Jannesar R, Rohani M et al. Comparison of deferoxamine, deferiprone and deferasirox iron-chelating agents in reducing serum ferritin levels in patients with thalassemia major. Journal of Clinical Care and Skills. 2020 Jul; 1(4): 189-93. doi: 10.52547/jccs.1.4.189. DOI: https://doi.org/10.52547/jccs.1.4.189

Syed A, Asif MH, Waheed R, Haider A, Ayub MA, Sidrah. Comparing deferasirox and desferrioxamine as iron chelators in patients with beta-thalassemia major. Journal of Population Therapeutics and Clinical Pharmacology. 2023 Oct; 30(17): 1937-1942. doi: 10.53555/jptcp.v30i17.2880.

Salem A, Desai P, Elgebaly A. Efficacy and Safety of Combined Deferiprone and Deferasirox in Iron-Overloaded Patients: A Systematic Review. Cureus. 2023 Nov; 15(11). doi: 10.7759/cureus.48276. DOI: https://doi.org/10.7759/cureus.48276